Chronic Kidney Disease in 68 Markets – Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2033
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
Chronic Kidney Disease Market Report Overview
The chronic kidney disease market size across the 68M was $4 billion in 2023. The chronic kidney disease market will witness significant growth during the forecast period.
Chronic Kidney Disease Market Outlook, 2023-2033 ($ Billion)
Buy the Full Report to Know More about the Chronic Kidney Disease Market Forecast
The chronic kidney disease market report covers 68 geographical markets and provides a forecast model for the market through 2033. The report covers sales forecast extrapolations for 7 major markets and an additional 61 geographical markets.
| Market Size (2023) | $4 billion |
| Key Countries | · Africa
· APAC · Europe · LATAM · Middle East · North America |
| Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Chronic Kidney Disease Market Segmentation by Regions
APAC accounted for the highest chronic kidney disease market share in 2023.
The key regions in the chronic kidney disease market are Africa, APAC, Europe, LATAM, the Middle East, and North America. North America and Europe also had a significant share of the chronic kidney disease market.
Chronic Kidney Disease Market Analysis by Regions, 2023 (%)
Buy Full Report for More Country Insights into the Chronic Kidney Disease Market
Key 7MM Events Driving the 68M Forecast Extrapolation
A few of the key events occurring in the 7MM that drive the trajectory of the 68M forecast for chronic kidney disease between 2023 and 2033 are Minnebro Launch, Ozempic Launch, Mitchga Launch, and Baxdrostat Launch among others.
Chronic Kidney Disease Regional Outlook (Value, $ Billion, 2023-2033)
- Africa
- APAC
- Europe
- LATAM
- Middle East
- North America
Scope
This publication is an expanded version of the Excel model containing the patient-based forecast sales for Chronic Kidney Disease (CKD), covered in GlobalData’s report “Chronic Kidney Disease: Seven -Market Drug Forecast and Market Analysis”, published in June 2024. In addition to patient based forecast sales data for the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan), this report contains sales forecast extrapolations for an additional 60 geographical markets (60M), totaling 68 markets (68M).
Key Highlights
- The proportion of people at risk of developing CKD is expected to increase over the 10-year forecast period due to the growing disease prevalence.
- The potential launch of 5 late-stage pipeline agents will increase the number of patients who can be offered pharmacological treatment options. In addition, novel drugs in late-stage development are expected to have a high annual cost of therapy (ACOT), a factor that will contribute to notable profitability.
- Despite multiple therapies currently available to CKD patients, there is still a high level of unmet need within the treatment space. The most recognizable is the need for novel therapies targeting new mechanisms and improving access to novel therapies.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the 7MM CKD therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM CKD therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Boehringer Ingelheim
Mitsubishi Tanabe Pharma
Reata Pharma
Novo Nordisk
KBP- Biosciences
Table of Contents
Table
Figures
Frequently asked questions
-
What was the chronic kidney disease market size across the 68M in 2023?
The chronic kidney disease market size across the 68M was valued at $4 billion in 2023.
-
Which region had the highest share in the 68M chronic kidney disease market?
North America held the highest share in the chronic kidney disease market across the 68M in 2023.
-
What are the key 7MM events driving the 68M forecast extrapolation?
A few of the key events occurring in the 7MM that drive the trajectory of the 68M forecast for chronic kidney disease between 2023 and 2033 are Minnebro Launch, Ozempic Launch, Mitchga Launch, and Baxdrostat Launch among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Chronic Kidney Disease (Chronic Renal Failure) reports

